drugset / Trial / NCT03904862
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
Phase 1/2
Terminated
21 enrolled
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI) · collabSenhwa Biosciences, Inc. · collabSt. Jude Children's Research Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multi center, Phase I, Phase II and surgical study of the CX-4945 drug (silmitasertib sodium) for patients with recurrent SHH (Sonic Hedgehog) medulloblastoma
Timeline
- Start
- 2019-07-25
- Primary completion
- 2025-08-11
- Completion
- 2025-08-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Silmitasertib | Small molecule | 600 mg/m2 | Oral |
| Subject | Silmitasertib | Small molecule | 1000 mg | Oral |